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ABSTRACT: There has been sustained focus on the secondary prevention of coronary heart disease and heart failure; yet, apart 
from stroke prevention, the evidence base for the secondary prevention of atrial fibrillation (AF) recurrence, AF progression, 
and AF- related complications is modest. Although there are multiple observational studies, there are few large, robust, rand-
omized trials providing definitive effective approaches for the secondary prevention of AF. Given the increasing incidence and 
prevalence of AF nationally and internationally, the AF field needs transformative research and a commitment to evidenced- 
based secondary prevention strategies. We report on a National Heart, Lung, and Blood Institute virtual workshop directed 
at identifying knowledge gaps and research opportunities in the secondary prevention of AF. Once AF has been detected, 
lifestyle changes and novel models of care delivery may contribute to the prevention of AF recurrence, AF progression, and 
AF- related complications. Although benefits seen in small subgroups, cohort studies, and selected randomized trials are 
impressive, the widespread effectiveness of AF secondary prevention strategies remains unknown, calling for development 
of scalable interventions suitable for diverse populations and for identification of subpopulations who may particularly benefit 
from intensive management. We identified critical research questions for 6 topics relevant to the secondary prevention of AF: 
(1) weight loss; (2) alcohol intake, smoking cessation, and diet; (3) cardiac rehabilitation; (4) approaches to sleep disorders; (5) 
integrated, team- based care; and (6) nonanticoagulant pharmacotherapy. Our goal is to stimulate innovative research that will 
accelerate the generation of the evidence to effectively pursue the secondary prevention of AF.
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The secondary prevention of atrial fibrillation (AF) is of major public health importance because the incidence, prevalence, and lifetime risk of AF are 
increasing in the United States and globally.1 AF also 
predisposes to major morbidities, including ischemic 
stroke, other systemic embolism, dementia, heart fail-
ure, myocardial infarction, chronic kidney disease, di-
minished quality of life, functional limitations, increased 
healthcare use, higher costs, and excess death.1 
Research into the secondary prevention of AF is critical 
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because with the exception of stroke prevention, the 
evidence base for the prevention of AF recurrence, AF 
progression, and AF- related complications lacks ro-
bust data in the general population, in contrast with the 
strong evidence base underlying guidelines for sec-
ondary prevention of coronary heart disease and heart 
failure with reduced left ventricular ejection fraction.
There also is a need for evidence- based strategies 
to address the secondary prevention of AF in high- risk 
subgroups because of the disproportionate burden of 
worse AF outcomes in women, systemically disadvan-
taged groups (eg, Black/Hispanic/Indigenous individ-
uals), and older adults. A meta- analysis of 30 studies 
reported that compared with men, women with AF had 
significantly higher relative risks for all- cause mortality, 
stroke, cardiac events, and heart failure.2 In the commu-
nity, compared with White individuals, Black individuals 
with AF had about 1.5- fold to 2- fold higher rate differ-
ences (rate in those with versus without AF) for stroke, 
heart failure, coronary heart disease, and death.3
The care of AF has largely been relegated to inter-
ventions that can be provided only by healthcare pro-
viders, but emerging evidence favors the critical role of 
lifestyle factors, which are more directly determined by 
patients themselves. The efficiency of public health ini-
tiatives may be enhanced by informing patients and the 
lay public about modifiable behaviors that influence their 
AF risk, signifying the need for particular lifestyle- related 
research initiatives in the secondary prevention of AF.
Over a decade ago, the National Heart, Lung, and 
Blood Institute (NHLBI) convened a workshop to pro-
mote research into the primary prevention of AF.4 From 
2019 through 2021, the NHLBI is convening a series 
of 7 virtual workshops to again promote acceleration 
of high- priority research in AF. The innovative virtual 
format provides an effective way to assemble interna-
tional experts to identify the most pressing research 
gaps and to articulate the highest- priority research 
challenges. The other webinars examined research 
priorities for AF ablation,5 bidirectional relations with 
heart failure,6 screening,7 stroke prevention, and mo-
lecular mechanisms; the final webinar will address so-
cial determinants of AF.
Our special report summarizes the proceedings of 
the NHLBI virtual workshop on the secondary preven-
tion of AF recurrence, progression, and complications, 
which occurred on May 15, 2020. The scope of the 
special report does not include the relationship of ab-
lation to secondary prevention,5 the specific topic of 
secondary prevention of heart failure in AF,6 or an in- 
depth examination of molecular/genetic mechanisms 
underlying AF, which were covered by other work-
shops. Expert participants identified major knowledge 
gaps and prioritized opportunities in 6 broad areas 
of AF secondary prevention research: (1) weight loss 
and body composition; (2) alcohol intake, smoking 
cessation, and diet; (3) cardiac rehabilitation (CR); (4) 
approaches to sleep disorders; (5) integrated, team- 
based care; and (6) nonanticoagulant pharmacother-
apy. Our goal is to stimulate innovative research that 
will accelerate development of effective strategies for 
the secondary prevention of AF.
WEIGHT LOSS AND BODY 
COMPOSITION
Background
Obesity is a global epidemic. Population- based studies 
have reported that obesity is strongly associated with 
the risk of incident AF, with a 29% increase in AF inci-
dence for every 5- unit increase in body mass index.8 
Genetic Mendelian randomization studies also sup-
port a causal association between obesity and AF; per 
1- kg/m2 body mass index, the age- and sex- adjusted 
hazard ratio (HR) for AF is 1.15.9 Obesity is associated 
with higher AF burden and increased progression from 
paroxysmal to persistent AF.10 More important, obesity 
curtails the effectiveness of therapies aimed at main-
taining sinus rhythm.8
Weight loss achieved through lifestyle modifica-
tion or bariatric surgery has been associated with 
improvement in or reduced incidence of risk factors 
for AF, including elevated blood pressure, hypergly-
cemia, diabetes mellitus, sleep disorders, myocar-
dial infarction, and heart failure. In a randomized 
controlled trial (RCT), weight loss achieved through 
increased physical activity, significant caloric restric-
tion, and healthier eating choices was associated 
with improved blood pressure, sleep apnea, glyce-
mic control, and lipid profiles.11 Bariatric surgery was 
associated with sustained weight loss and remission 
of diabetes mellitus in meta- analysis of RCTs,12 and 
in meta- analysis of observational data with reduced 
incidence of diabetes mellitus, hypertension, sleep 
apnea, and coronary heart disease.13
Recent largely observational studies have demon-
strated that comprehensive approaches to treating 
risk factors, with a focus on targeting weight loss, 
Nonstandard Abbreviations and Acronyms
AMPK AMP- activated protein kinase
CR cardiac rehabilitation
HFpEF heart failure with preserved ejection 
fraction
NHLBI National Heart, Lung, and Blood 
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have been associated with reduction of AF symp-
toms and AF burden, and improvement in the main-
tenance of sinus rhythm and quality of life.14,15 There 
also is evidence for a reversal of AF progression with 
a transition from persistent to paroxysmal or no AF.16 
Emerging observational data suggest that similar 
findings may be achieved using bariatric surgery.17 
However, the risks of AF after bariatric surgery are 
complex and vary over time. Examining US adminis-
trative data from 4 states, investigators reported that 
the risk of AF- related emergency department visits 
and hospitalizations was increased in the 12 months 
after bariatric surgery (n=523 adults undergoing bar-
iatric surgery; adjusted odds ratio [OR], 1.53; 95% CI, 
1.13– 2.07; P=0.006).18 In longer- term follow- up (me-
dian, 7.9  years; interquartile range, 7.2– 19.0  years), 
a meta- analysis of 7 cohort studies observed that 
compared with referents, bariatric surgery (n=7681) 
was associated with an OR of 0.42 (95% CI, 0.22– 
0.83) for incident AF.19
On the basis of observational and clinical trial ev-
idence, the 2019 focused update of the American 
Heart Association/American College of Cardiology/
Heart Rhythm Society guideline document on AF 
included a class I, level of evidence B- R recom-
mendation of weight loss combined with risk factor 
modification in patients with AF who are overweight 
or obese.20 However, the 2020 European AF guide-
lines gave weight loss only a class IIa, level of evi-
dence B recommendation.21
Knowledge Gaps
Mechanisms for Development of the Substrate 
for AF
Experimental studies have demonstrated that obe-
sity directly affects the atrial myocardium with struc-
tural and electrophysiological changes, supporting 
the milieu for AF (Abed, 2013, number 3666). There is 
activation of both the transforming growth factor and 
endothelin pathways, and altered distribution of cell- to- 
cell connections. However, the signaling pathways that 
lead to these changes have remained elusive.
Studies have demonstrated that epicardial fat and 
myocardial fat infiltration increase in obesity.22 The se-
cretome of epicardial fat has been demonstrated to 
promote the AF substrate, including myocardial fibro-
sis.23 However, the constituents and mechanisms as-
sociated with this phenomenon remain unknown.
Obesity is associated with numerous comorbidi-
ties, including hypertension, diabetes mellitus, sleep 
apnea, heart failure, and myocardial infarction, that 
are known to be associated with AF,24,25 although 
obesity remains a risk factor for AF after adjustment 
for coexistent risk factors.26 However, the signaling 
pathways and the interaction between obesity and 
associated comorbidities on the risk of AF remain in-
completely understood.
Reversibility of the AF Substrate
Clinical studies have demonstrated that the AF sub-
strate can be reversed with substantial weight loss and 
risk factor management.16 In an experimental model of 
obese sheep, 30% weight loss was associated with atrial 
electrophysiological and structural reverse remodeling, 
and improved inflammatory and growth factor markers; 
the changes were accompanied by a reduced propen-
sity for AF independent of other AF risk factors, includ-
ing elevated blood pressure. However, the mechanisms 
by which weight loss and risk factor management alter 
the AF substrate remain only partially determined.
Generalizability of Studies
In a modest- sized (n=150), single- center, short- term 
randomized study of patients with AF, investigators in 
Adelaide, Australia, have reported achieving remark-
able weight loss, reductions in AF symptoms and bur-
den, and improved maintenance of sinus rhythm.11 
A meta- analysis of the Adelaide groups’ 5 studies (4 
observational and 1 RCT, total 548 patients) reported 
that at least 10% weight loss in overweight and obese 
individuals was accompanied by at least 71% less AF 
recurrence and significantly lower episode length and 
symptom severity.15
Studies replicating the marked sustained weight 
loss and AF burden improvement through lifestyle 
modification observed in the Australian studies have 
not been reported from other investigators,27 other 
countries, and more racially/ethnically and socio-
economically diverse populations. Implementation 
of weight loss programs requires the development 
of reproducible and effective tools and strategies for 
achieving sustained weight loss and other risk fac-
tor modification in diverse populations and health 
systems.
Clinical Outcomes
Developing effective secondary prevention imple-
mentation strategies in diverse populations with AF 
is critical given sex, racial/ethnic, and socioeconomic 
inequities in clinical outcomes after recognition of 
AF.1– 3 It is essential to design adequately powered 
studies including diverse individuals (age, sex, racial/
ethnic, and socioeconomic status) to evaluate the 
potential influence of weight loss on AF recurrence 
and burden, and clinical outcomes such as stroke, 
cognitive decline, myocardial infarction, heart failure, 
quality of life, healthcare use, cost- effectiveness, 
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points have been complex and resource intensive. 
Hence, innovative, pragmatic, clinical trials will be 
critical to addressing the relations between second-
ary prevention and outcomes. The mechanisms, 
consequences, and critical research opportunities 
relating obesity to the secondary prevention of AF 
are illustrated in Figure 1.
Research Opportunities
1. Identify populations in whom successful weight 
loss leads to reversal of the atrial substrate for 
AF, and determine the mechanisms associated 
with the reversibility of epicardial fat and atrial 
fibrosis/substrate, including weight loss per se and 
regression of the comorbidities associated with 
obesity.
2. Develop and test effective, reproducible, scalable 
tools and strategies required to achieve and sustain 
significant weight loss and risk factor management 
over the long- term in diverse populations (eg, age, 
sex, race/ethnicity, and socioeconomic status) with 
AF and then implement the appropriate public health 
initiatives in different health systems and diverse 
populations.
3. Conduct multicenter pragmatic RCTs of the effect of 
weight loss, including bariatric surgery and risk fac-
tor management, in diverse individuals with AF on 
AF recurrence, burden, progression, and outcomes, 
including stroke, cognitive decline, heart failure, 
myocardial infarction, quality of life, healthcare use, 
costs, and mortality.
ALCOHOL, SMOKING, AND DIET
Background
Extensive observational evidence indicates that exces-
sive alcohol consumption28 and cigarette smoking29 
are associated with the risk of developing AF, whereas 
the data linking diet and AF are less consistent.30,31 
Understanding of the effect of alcohol, smoking, and 
dietary interventions on the secondary prevention of 
AF is more limited.
Alcohol Intake
A meta- analysis of the association of alcohol con-
sumption with incident AF demonstrated a convincing 
dose- response relationship (adjusted relative risk by 
Figure 1. Current knowledge and prioritized research opportunities to advance atrial fibrillation (AF) secondary prevention 
through weight management.
The figure highlights known associations and the consequences that link obesity with AF. Weight loss has been demonstrated in 
the short- term to reduce AF burden when performed in the context of a comprehensive risk factor management program. However, 
there remain several research priorities, highlighted in the blue panels, that are required to (1) improve our understanding of the 
mechanisms; (2) improve the tools and strategies to achieve sustained weight loss; and (3) evaluate the outcomes of sustained weight 
loss. Figure is original, created with BioRe nder.com. BMI indicates body mass index; DM, diabetes mellitus; LA, left atrial; and OSA, 
obstructive sleep apnea.
ACHIEVING SUSTAINED WEIGHT LOSS
• Develop and test reproducible tools, strategies 
and teams to achieve and sustain weight loss and 
risk factor management over the long term in 
diverse populaons
• Implement appropriate public health iniaves in 
different health systems and diverse populaons
REVERSAL OF ATRIAL SUBSTRATE
• Idenfy responders
• Idenfy mechanisms and factors associated with 
epicardial fat and the formaon of the AF 
substrate and the factors associated with 
reversibility of atrial fibrosis/substrate
• Evaluate the interplay of risk factors with atrial 
remodeling pathways
EVALUATE LONG-TERM OUTCOMES
• Conduct pragmac randomized clinical trials to 
determine the impact of weight and risk factor 
management in individuals with AF on AF 
recurrence, burden, progression, and 
cardiovascular outcomes including stroke, 
cognive funcon, heart failure, health care 
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drinks per day was 1.08 for 1, 1.17 for 2, 1.26 for 3, 1.36 
for 4, and 1.47 for 5).28 Alcohol intake is a common 
trigger for AF episodes32 and has been associated 
with atrial enlargement,33 adverse electrical atrial re-
modeling,34 and higher risk of AF recurrence after ab-
lation.35 An Australian open- label RCT of 140 patients 
(15% women; mean age, 62 years) with paroxysmal or 
persistent AF who consumed ≥10 drinks per week ran-
domized half to abstain and half to usual alcohol con-
sumption.36 Patients in the abstinence group reduced 
their alcohol consumption by 88% and experienced 
longer periods before AF recurrence and reduced AF 
burden.36
Smoking
A meta- analysis of observational studies reported a 
dose- response association between cigarette smok-
ing and incident AF.29 There is limited evidence linking 
smoking with secondary prevention of AF. In an ob-
servational study, smoking was found to be a predic-
tor of AF recurrence after ablation and was therefore 
included in a risk score for recurrent AF (adjusted HR, 
1.88 [95% CI, 1.40– 2.51]).37 Proposed mechanisms in-
clude proarrhythmogenic effects of nicotine as well as 
the overall adverse association of smoking with cardio-
vascular risk.38
Diet
Few studies have evaluated whether specific dietary 
patterns, foods, or nutrients improve outcomes in 
AF. Fish oil supplementation has been tested as a 
potential intervention for AF secondary prevention, 
but results have shown inconsistent effects.39 The 
Vital- Rhythm Study (NCT02178410), a 2×2 facto-
rial RCT, revealed that neither omega- 3 fatty acids 
nor vitamin D reduced or increased incident AF.40 A 
post hoc analysis of a large RCT reported a protec-
tive effect of the Mediterranean dietary pattern on AF 
incidence.41 On the basis of these findings, a new 
study (NCT03053843) is testing the effectiveness 
of this dietary pattern to reduce AF recurrence after 
ablation.42
Knowledge Gaps
Most research into the influence of modifiable expo-
sures, such as alcohol, smoking, and diet, on AF risk 
has focused on long- term patterns of consumption 
as predictors of new- onset disease among cohorts of 
individuals, leaving 3 overarching gaps in knowledge: 
(1) the effects of these exposures and interventions 
among those already diagnosed with the disease, in-
cluding AF recurrence and complications; (2) the risk of 
an immediate exposure, such as a particular drinking 
event, a cigarette smoked, or short- term ingestion of a 
dietary component, and the near- term risk of a discrete 
AF event; and (3) how interactions with common ge-
netic variants may result in heterogeneity of these ef-
fects among individuals (Figure 2). Specific knowledge 
gaps include the following.
Alcohol
It is important to determine whether regular light to 
moderate alcohol consumption (such as one drink 
per day) increases the risk of recurrent AF given ob-
servational studies reporting cardiovascular benefits 
compared with no alcohol intake. The mechanisms 
by which short- term consumption can induce dis-
crete episodes and the mechanisms linking long- 
term alcohol consumption to AF are important 
knowledge gaps. There also is a lack of AF second-
ary prevention data with respect to drinking patterns 
(eg, frequency of drinking for the same amount of al-
cohol, such as consumption of multiple drinks on the 
same day compared with an equal amount split over 
a week, and with or without meals). It would be useful 
to definitively determine whether alcohol cessation 
improves the effectiveness of ablation and pharma-
cologic therapies and decreases the complications 
after AF onset.
Smoking
Whether and to what extent smoking cessation 
can reduce the burden and complications of AF 
remain an important knowledge gap. It is also un-
certain whether electronic cigarettes are associated 
with an increased risk of AF. In addition, it will be 
important to determine effective implementation 
strategies to ensure individuals with AF who smoke 
receive evidence- based effective smoking cessation 
interventions.
Diet
Identifying which dietary components (nutrients and 
foods) or dietary patterns acutely or chronically in-
crease or decrease the risk of discrete AF events or 
burden and complications is important. How certain 
diets can chronically influence left atrial remodeling 
and affect AF burden has yet to be determined.
The most compelling evidence for the effectiveness 
of alcohol consumption, smoking, and dietary factors 
will be derived from RCTs. In addition, a major unmet 
need is to develop resource- effective policies and 
pragmatic implementation approaches to scale inter-
ventions to diverse communities (age, sex, race/eth-
nicity, and socioeconomic status) and to enhance the 
sustainability of lifestyle behaviorally based interven-
tions. For instance, can programs be implemented in 
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barbershops, and gyms? Can digital health and wear-
able technologies be harnessed to improve adherence 
to lifestyle modification and monitor AF recurrence and 
burden?
Research Opportunities
1. RCTs of specific interventions, including (1) alco-
hol reduction or abstinence; (2) intensive smoking 
cessation; and (3) heart healthy diets (eg, Dietary 
Approaches to Stop Hypertension type, plant based, 
and Mediterranean), versus usual care should be 
conducted, evaluating their efficacy in reducing AF 
burden or recurrence, improving quality of life, and 
reducing complications among diverse patients (eg, 
age, sex, gender, race/ethnicity, and socioeconomic 
status) with AF, including those with new- onset 
disease, those with paroxysmal AF, postcardiover-
sion, and individuals managed with pharmacological 
therapies or AF ablation procedures.
2. Develop and test implementation strategies to scale 
and sustain lifestyle interventions proven to be ef-
fective for secondary prevention of AF, potentially in-
cluding (1) reducing or avoiding alcohol; (2) intensive 
smoking cessation; and (3) heart healthy diets in di-
verse communities and community- based settings; 
and study their effect on AF recurrence, AF burden, 
quality of life, healthcare use, and complications (eg, 
stroke, cognitive decline, heart failure, myocardial in-
farction, frailty, and death).
3. Test the effectiveness of digital health and wearable 
technologies to enhance adherence to effective life-
style interventions (alcohol and smoking cessation 
and dietary modification) in diverse communities and 
community- based settings, and study their effect on 
AF burden, AF recurrence, quality of life, healthcare 
use, and AF complications.
EXERCISE AND CR PROGRAMS
Background
Exercise, lifestyle modification, and CR have the poten-
tial to mitigate the intrinsic pathophysiological features 
of AF, improve other AF risk factors (eg, blood pressure, 
obesity, and sleep), and improve outcomes (eg, hospi-
talization, physical function, and quality of life) in those 
with AF.43 CR is a multifaceted approach that links exer-
cise training with elements of risk factor reduction (eg, 
tobacco, unhealthy diet, obesity, and hypertension) for 
patients with known cardiovascular disease.44,45
A meta- analysis of 22 observational studies 
(n=656 750 participants) reported that sedentary life-
style was associated with increased risk of incident 
Figure 2. Current knowledge and prioritized research opportunities to advance atrial fibrillation (AF) secondary prevention 
through modifying alcohol consumption, smoking, and diet.
Alcohol, smoking, and various dietary patterns, foods, and nutrients may lead to discrete episodes of recurrent AF via acute changes, 
such as proarrhythmic autonomic effects (top left) or acute electrophysiologic effects (bottom left), or may lead to greater propensity 
for AF via chronic structural changes, such as diffuse left atrial remodeling (manifested as low voltages as shown in the left atrial 
electroanatomic map in the upper right) and left atrial enlargement (as shown in the echocardiographic images in the bottom left). 
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AF (OR, 2.47 [95% CI, 1.25– 3.7]), whereas women 
(OR, 0.91 [95% CI, 0.78– 0.97]) and men (OR, 0.81 
[95% CI, 0.26– 1.004]) engaging in moderate physical 
activity were less likely to develop AF.46 However, a 
J- shaped relation to physical activity has been noted, 
with men engaged in vigorous physical activity hav-
ing significantly higher risk of AF (OR, 3.30 [95% CI, 
1.97– 4.63]).46
AF is not a primary indication for CR in AF guide-
lines,20,21,47 which potentially undercuts an opportunity 
to improve care for adults who are afflicted with AF or 
who seek primary ablative therapies. The data for sec-
ondary prevention of AF with CR are based on modest 
numbers of participants and studies. A meta- analysis 
by Smart et al of 9 studies (1 observational and 8 ran-
domized) reported CR was not associated with re-
duction in all- cause mortality but was associated with 
improvements in health- related quality of life, exercise 
capacity, and AF symptom burden.48
Knowledge Gaps
Existing studies of CR on secondary prevention of 
AF were small and largely short- term (≤6  months), 
had heterogeneous inclusion criteria, varied CR pro-
tocols and interventions, and diverse outcomes, and 
were unable to determine the effect of CR on types 
of AF or the optimal training intensity (see Table S1 for 
published CR trials in AF).48 For instance, the Smart 
et al meta- analysis study was modestly powered; the 
included studies comprised 483 exercise- based CR 
participants and 476 controls. The generalizability of 
the findings to most individuals with AF was also un-
certain as the mean age of participants was typically 
≤70  years and most studies included <30% women 
(Table S1). Furthermore, none of the studies reported 
on level of educational attainment; only 1 reported on 
household income; and only 3 specified race (most 
were European ancestry), of which 2 specified race as 
White race or other (other race, 3% and 15%), whereas 
in 1 study, 20% (n=78) of those with AF studied were 
Black individuals.49 Most of the studies of AF and CR 
registered in ClinicalTrials.gov also are small, are single 
center, and have many of the limitations of prior studies 
(Table S2).
Specific subgroups of patients with AF to target for 
CR trials include the following (Figure 3).
Diverse Individuals
The RCT evidence base for CR is modest, and par-
ticularly limited for women, participants with lower 
educational attainment/income, and individuals of di-
verse races/ethnicities. Social determinants of health 
and ethnic/racial disparities in access to care, as well 
as inherent cultural differences, also may influence 
how CR is applied or used. Large, high- quality RCTs 
are needed to evaluate the efficacy of CR for second-
ary prevention of AF with adequate representation of 
women, individuals with lower educational attainment/
income, and participants who are Black, Asian, Pacific 
Islander, Indigenous, or Hispanic race/ethnicity.
Older Individuals
The incidence and prevalence of AF increase dramati-
cally with advancing age, yet there is a paucity of data 
for the effectiveness and safety of CR in older adults 
with AF. Older age is also accompanied by multiple 
comorbidities, alterations in muscle composition and 
strength, inflammation, and poorer attendance to 
center- based CR.50
Heart Failure With Preserved Ejection Fraction
Older age also is associated with increased preva-
lence of heart failure with preserved ejection fraction 
(HFpEF) that also is conducive to AF. The benefits of 
CR for AF with comorbid HFpEF, a growing popula-
tion, are uncertain.51 The RACE3 (Routine versus 
Aggressive upstream rhythm Control for prevention of 
Early persistent atrial fibrillation in heart failure study 3) 
RCT of patients with AF and mild- to- moderate heart 
failure (both reduced and preserved left ventricular 
ejection fraction) reported that an intervention consist-
ing of mineralocorticoid receptor antagonists, statins, 
angiotensin- converting enzyme inhibitors, or angio-
tensin receptor blockers, and CR resulted in a higher 
likelihood of sinus rhythm at 1 year (75% versus 63% 
in conventional care; OR, 1.8; P=0.04).52 However, the 
study had limited power to detect whether CR had the 
same benefit in individuals with preserved versus re-
duced ejection fraction. The degree to which the CR 
component of the intervention was responsible for the 
improved outcomes also was uncertain.
Another area of interest is the role of specific CR 
elements or alternative CR locations.
Specific CR Elements
Optimal exercise training modes and intensities for 
AF prevention remain undetermined. Although there 
is evidence for greater cardiorespiratory benefits 
with higher- intensity interval training, its applica-
tion to AF prevention remains controversial because 
of concerns that it could potentially exacerbate the 
arrhythmia.46 Similarly, there is evidence for yoga53 
and Tai Chi54 as training modes that afford integrated 
cardiovascular, respiratory stretching, and medita-
tive benefits, but it is not clear they achieve suffi-
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Mobile- and Home- Based CR
There is growing awareness that patients often pre-
fer to exercise outside the hospital, but home- based 
or mobile health- based CR is highly understudied in 
AF. In one small RCT of 158 patients referred for CR 
after heart valve surgery or AF ablation, patients could 
choose center- based (n=87) or self- managed home 
(n=71) CR.55 Of note, regardless of setting, patients 
had similar benefits in physical functioning and self- 
reported quality- of- life outcomes (with the exception 
of modestly higher mean depression score in the 
center- based CR; AF recurrence was not assessed). 
The COVID- 19 pandemic has underscored the desir-
ability of home- and mobile health- based exercise 
options.
Molecular Markers of CR Efficacy
Another understudied area of CR in AF is how po-
tential mechanistic biomarkers correlate with efficacy 
of CR in reducing recurrent AF. Biomarkers (eg, ge-
netics, molecular signals, imaging indexes, and in-
flammation)56 may identify causal mechanisms and 
prognostic benchmarks for AF. Once identified, such 
biomarkers may be applied for participant selection 
Figure 3. Figure showing the complexities of secondary prevention of atrial fibrillation (AF) with cardiac rehabilitation (CR).
Inner hexagon: core components of CR include exercise training, risk factor reduction, education, lifestyle and behavior modification, 
and addiction curtailment (eg, alcohol and smoking), as well as new models of home- based care that may all provide utility for AF, 
but specific benefits of multifaceted CR for AF remain poorly studied. Colored hexagons: (top to clockwise) depict some of the many 
issues that affect CR, and influence AF (eg, cardiovascular disease, race and ethnicity, sex, older age, frailty, and obesity). All remain 
poorly studied in relation to CR and AF. Red labels: (top to clockwise) depict some of the complex dynamics that factor into the 
limitations of contemporary CR research and clinical care.
• Lack of randomized controlled trials (RCTs) inclusive of diverse demographics, including sex, race, and ethnicity, as well as broader 
functional end points that may better reflect utility of CR for AF.
• Lack of precision in regard to exercise modes and intensities, with understanding of both physiological and behavioral implications 
that factor into CR for AF.
• Lack of inclusion of older adults with focus on related complexities of frailty, sarcopenia, cognitive changes, and intrinsic aging 
physiological features that may factor into particular benefits of CR for AF.
• Lack of inclusion of obese subgroups with distinctive behavioral, biological, and clinical challenges pertaining to CR for AF.
Black lettering (left top to clockwise) highlights some of the factors needed for improved AF research within CR:
• *Broad CR outcomes.
• †Broad range of pertinent AF outcomes.
• Research opportunities.
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or as modifiable surrogate end points to evaluate the 
relative utility of different exercise options and/or other 
CR treatments.
Research Opportunities
1. Observational studies and RCTs of CR should 
oversample understudied subgroups of patients 
with AF, including older adults, women, Black/
Hispanic/Asian/Pacific Islander/Indigenous individu-
als, HFpEF, and individuals with lower educational 
attainment/income. Outcomes should include suc-
cess of risk factor modification (eg, if indicated 
smoking/alcohol cessation, weight loss, and control 
of blood pressure and diabetes mellitus) and AF- 
related symptoms, recurrence, progression, and 
clinical complications.
2. RCTs should examine innovative implementation of 
CR strategies and their potential efficacy for reduced 
AF recurrence and complications in diverse repre-
sentative AF populations:
• Harnessing technology: virtual care with apps and 
wearables.
• Home- based and hybrid models.
• High- intensity interval training versus lower- 
intensity regimens (eg, yoga and tai chi).
3. Substudies of CR observational studies and RCTs 
should examine the association of CR with AF- related 
biomarkers, including biomarkers of inflammation, 




Sleep disorders and disturbances are common, share 
risk factors with cardiovascular disease, and are impli-
cated as causal factors in multiple chronic health prob-
lems. Of the sleep disorders, obstructive sleep apnea 
(OSA) has been most studied in relationship to AF. 
OSA is present in 21% to 74% of patients with AF57 and 
is associated with increased hospitalization rates and 
symptom burden,58 and recurrent AF after cardiover-
sion.59 Meta- analyses estimate that untreated OSA is 
associated with a 40% increased risk of AF recurrence 
after catheter ablation.60
There are well- described physiological mecha-
nisms linking OSA to AF incidence and recurrence 
through effects on atrial structural and electrical re-
modeling (eg, negative thoracic pressure swings in-
creasing atrial stretch/dilation and preload; hypoxia 
increasing afterload and triggering inflammatory 
and oxidative stress pathways; altered sympathova-
gal activity).61 The molecular mechanisms of OSA- 
related atrial fibrosis and conduction and sinus node 
abnormalities are less understood, but studies im-
plicate connexin remodeling, dysregulation of myo-
cardial excitation/coupling, and phosphorylation of 
sodium channels.62
Investigators have examined screening for and 
treating OSA as an approach to mitigating AF disease 
burden. Observational studies suggest that contin-
uous positive airway pressure (CPAP) is associated 
with reduced risk of recurrent AF after cardioversion59 
or catheter ablation.60 A lower recurrence rate fol-
lowing ablation therapy in patients with OSA treated 
with CPAP was reported to parallel CPAP- related re-
ductions in blood pressure, atrial size, and ventricular 
mass,63 supporting a potential physiological benefit of 
CPAP on risk of recurrent AF. However, there are no 
RCTs to support benefit. Only one small (n=25) RCT 
was conducted specifically to study AF recurrence, 
with negative results, but it was underpowered.64 SAVE 
(The Sleep Apnea Cardiovascular Endpoints) trial (2717 
participants; 37 AF events) also did not demonstrate 
a benefit of CPAP on new- onset AF; but AF was an 
underpowered secondary outcome.65
Recent studies suggest that other sleep disturbances 
that impair quality or quantity of sleep also may be as-
sociated with increased risk of AF, including short sleep 
duration,66 reduced rapid eye movement sleep,67 insom-
nia,67 and periodic limb movement disorder.68 However, 
some associations vary by age/sex, and the effect of 
these sleep disturbances on AF burden has not been 
addressed. Although circadian physiological features 
have profound effects on multiple organ systems and AF 
displays increased nocturnal occurrences,69 there is little 
research addressing circadian influences on AF.
Knowledge Gaps
Mechanisms and Identification of At- Risk Sleep 
Disorder Phenotypes
OSA is a complex heterogeneous disorder that gen-
erates physiological stressors related to variations in 
inspiratory obstruction, gas exchange abnormalities, 
arousal, and sleep disruption. Although the apnea- 
hypopnea index is most frequently used to characterize 
OSA, it does not comprehensively describe alterations 
in physiological stresses and underlying disease mech-
anisms, nor does it consistently predict all types of ad-
verse cardiovascular outcomes. In contrast, compared 
with the apnea- hypopnea index, measures of hypoxia 
better predict cardiovascular disease and death, as 
well as recurrent AF.70 There is thus a need to better 
understand the physiologic drivers of AF burden, the 
underlying phenotypes of individuals with OSA most at 
risk for AF, and the sleep metrics that best identify indi-
viduals likely to benefit from OSA treatment.
Mechanisms underlying the relations between 
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largely unknown and are worthy of additional study. 
Elucidating distinctions between chronic and acute 
effects may be revealing. For example, although mul-
tiple observational cohort studies have demonstrated 
chronic sleep disruption as a risk factor for incident dis-
ease,67 selected patients with AF describe acute lack of 
sleep as a common trigger of discrete AF episodes.32
Subgroup Susceptibility
In addition to identifying which OSA subtypes repre-
sent those most at risk for recurrent AF and related 
morbidity, there is incomplete understanding of how 
age, sex/gender, race/ethnicity, underlying heart dis-
ease, and comorbid sleep disorders (eg, insomnia and 
periodic limb movements) moderate risk. It is unknown 
whether the association between central sleep apnea 
and incident AF in community- based cohorts71 reflects 
risk associated with a unique central sleep apnea phe-
notype (eg, enhanced autonomic phenotype), or re-
flects primarily unrecognized subclinical heart disease 
present at baseline in individuals with central sleep 
apnea.
Screening
There is a need to understand what settings are most 
effective for screening for OSA/sleep disorders in pa-
tients with AF, and to understand which tools (eg, ques-
tionnaires, wearables, oximetry, and mobile health) 
have optimal predictive value. There are patient and 
health system barriers to sleep laboratory testing for 
OSA. Hence, the role of home- based screening and 
wearable technologies merits further research. There 
is also a need to better apply data analytics, includ-
ing machine learning, to data from remote monitoring 
of physiological signals (eg, from implantable devices) 
to improve screening72 and management of OSA and 
other sleep disorders (Figure 4).
Therapeutic Interventions
The literature on treating OSA in individuals with AF 
is largely limited to observational studies of CPAP, an 
intervention with variable tolerance and adherence. 
Adequately powered RCTs are needed that test CPAP 
coupled with interventions to enhance adherence,73 
as well as test other OSA interventions (mandibular 
Figure 4. Sleep disorders and atrial fibrillation (AF) burden: stressors, metrics, screening, and intervention.
A high proportion of patients with AF have obstructive sleep apnea (OSA) and other sleep disorders that can increase AF burden 
through atrial remodeling, autonomic nervous system (ANS) alterations, and metabolic/inflammatory pathways. AF burden may be 
reduced by improved understanding of the metrics and phenotypes that identify risk for sleep- related AF burden and implementing 
cost- effective screening. Randomized controlled trials (RCTs) are needed to evaluate the impact of sleep disorders screening/
treatment on AF burden. AHI indicates apnea- hypopnea index; CBTi, cognitive- behavioral therapy for insomnia; CSA, central sleep 
apnea; HR, heart rate; HSAT, home sleep apnea test; ML, machine learning; PAP, positive airway pressure; PLMS, periodic limb 
movements in sleep; and Rx, treatment.
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devices, hypoglossal/phrenic nerve stimulation, po-
sitional therapy, and others). Although OSA and obe-
sity aggregate, there are only a few studies that have 
begun to address multi– risk factor reduction strategies 
for reducing AF burden in sleep disorders.11
A major mechanism linking OSA to AF is the auto-
nomic nervous system; however, it remains uncertain 
how to apply novel interventions for AF risk reduction 
that target this mediating pathway (eg, renal sympa-
thetic nerve denervation, ablation of cardiac ganglia, 
low- level vagal or baroreflex stimulation, β blockers, 
and anti- inflammatory drugs).74
Research Opportunities
1. Conduct secondary analyses of observational and 
RCT databases to determine which sleep disorder 
metrics, subphenotypes, and risk clusters reflect 
the highest risk for recurrent AF and AF burden 
and complications. Develop new metrics derived 
by applying advanced signal analysis and machine 
learning to physiological signals collected during 
sleep (eg, polysomnography and electrocardiogra-
phy), used alone or combined with symptoms and 
other data to identify high- risk clusters, and test 
their role in predicting AF burden and complications.
2. Conduct pragmatic RCTs that compare alternative 
OSA screening approaches (eg, questionnaires, oxi-
metry, and wearables) for identifying patients with 
AF with clinically important levels of OSA (ie, at in-
creased risk for AF burden) and those likely to re-
spond to OSA- related interventions.
3. Conduct adequately powered RCTs that test inter-
ventions to improve sleep, examining recurrent AF 
and AF burden and complications in diverse sam-
ples of patients with AF to evaluate for potential 
differences in responses by age, sex, race/ethnic-
ity, and sleep disorder subtype, including patients 
undergoing AF ablation. Intervention targets should 
include OSA as well as insomnia, short sleep dura-
tion, and periodic limb movements, and test inter-
ventions that include but are not limited to CPAP (eg, 
mandibular advancement devices and cognitive- 
behavioral therapy for insomnia). Perform secondary 
analyses of observational and RCT data to evaluate 
the potential roles for tailored/individualized interven-
tions for treating patients with AF and OSA/central 
sleep apnea that target intermediate mechanisms 
(eg, neurohumoral modulation and anti- inflammatory 
therapy).
INTEGRATED, TEAM- BASED CARE
Background
AF poses a high burden on the healthcare system; 
in the United States, AF accounts for $28.4  billion 
(US$2016) dollars in healthcare spending; about 
29.8% of healthcare costs are for AF- related hospi-
talizations and 29.4% for ambulatory care.75 Moreover, 
AF management can be complex and demanding 
and should include rate control, rhythm management, 
stroke prevention, risk factor management, and life-
style modification.44,76
Multiple studies have demonstrated the impor-
tance of risk factor modification to significantly reduce 
the burden of AF and maintain sinus rhythm.14,15,52 
Questions have emerged, including whether such 
comprehensive care can be appropriately provided by 
a single healthcare professional and what is the opti-
mal role of the patient in managing AF.
Novel models of AF care have been identified to 
prevent fragmentation of care and potentially im-
prove clinical outcomes. Integrated care in this con-
text is an approach that includes 4 fundamental and 
indispensable elements47: (1) active involvement of 
the patient, including shared decision- making and 
self- management; (2) a multidisciplinary team ap-
proach; (3) use of technology to support integrated 
care; and (4) a comprehensive care approach involv-
ing rate and rhythm control, anticoagulation, and risk 
factor management, as appropriate. International 
guidelines for clinical AF management recommend 
integrated care as the leading approach to manage 
AF, to improve guideline adherent therapy, and to 
improve outcomes. The Australian and New Zealand 
Guidelines considered integrated care to have a high 
strength level and high evidence grade,47 whereas in 
2020, the European Guidelines gave integrated man-
agement (AF Better Care holistic pathway) a class IIa 
recommendation, level of evidence B.21 In contrast, 
the US guidelines do not address the topic of inte-
grated care.20
Initial studies (meta- analysis, 3 studies with 1383 
patients,77 and post hoc analysis of an RCT with 712 
patients newly diagnosed with AF78) have demon-
strated promising results in relation to integrated care 
in patients with AF with significantly reduced cardio-
vascular hospitalizations and mortality,77,78 and bet-
ter cost- effectiveness compared with usual care.79,80 
A recent multicenter study of 1375 patients (44% 
women; mean age, 64 years) with AF, however, did 
not demonstrate significant differences in cardiovas-
cular hospitalization and mortality between 671 ran-
domized to nurse- led care versus 683 in usual care in 
the primary analysis.81 However, a prespecified sub-
group analysis demonstrated that the benefits of in-
tegrated care were heterogeneous (Pinteraction<0.001); 
nurse- led care appeared beneficial in experienced 
centers (HR, 0.52 [95% CI, 0.37– 0.71]), but not in in-
experienced centers (HR, 1.24 [95% CI, 0.94– 1.63]).81 
Given the ongoing increasing prevalence of AF, novel 




 http://ahajournals.org by on O
ctober 10, 2021
J Am Heart Assoc. 2021;10:e021566. DOI: 10.1161/JAHA.121.021566 12
Benjamin et al AF Secondary Prevention Research Priorities: NHLBI
care, should be investigated and improved to provide 




Integrated care has been defined by international 
guidelines as having the 4 fundamental elements out-
lined above. Some interventions have been reported 
as representing integrated care despite not including 
all 4 fundamental elements, such as studies includ-
ing patient education82 and the AF Better Care path-
way.83 It is uncertain whether each of the 4 elements 
of integrated care are essential, or whether equivalent 
outcomes could be achieved with specific elements of 
integrated care in defined subgroups of patients with 
AF (Figure 5).
Selection of Patients for Integrated Care
Can we define subgroups of individuals with AF who 
will most benefit from integrated care, and conversely 
identify subgroups who will not have better outcomes 
with team- based care and avoid the associated 
costs?
Team- Based Approach as a Fundamental 
Element of Integrated Care Is Understudied
The general belief is that team- based approaches 
are expensive. However, data on the relative 
benefits versus costs of integrated care in AF are 
scarce and have not been reported from the United 
States.
Practical Implications of Establishing a 
Dedicated AF Team for Individual Patients 
With AF
Uncertainties exist on how to build a systematic ap-
proach to improve outcomes while preventing frag-
mentation of care. What are the practical implications 
and considerations to implement a team- based ap-
proach in clinical practice, particularly in the midst of 
the current pandemic?
Optimal Outcomes and Experience Measures of 
Integrated Care Pathways
What are the most relevant outcomes to assess 
in relation to integrated care? Is it sufficient to im-
prove patient- reported outcome and experience 
Figure 5. Integrated team- based care in atrial fibrillation (AF).
The integrated team- based care for AF management comprises 4 crucial fundamentals: (1) patient- centered care with active role 
for patients; (2) multidisciplinary team approach; (3) use of technology to support integrated care; and (4) comprehensive treatment 
comprising AF management, prevention of thromboembolic complications, cardiovascular risk factor management, and lifestyle 
modification, which is steered by evidence- based guideline recommendations. IC indicates integrated care; RCT, randomized 
controlled trial; and UC, usual care.
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Background
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• Paent involvement
• Muldisciplinary team
• Technology to support integrated care
• Comprehensive treatment
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measures, including patient perceived burden of 
care, or must integrated care also demonstrate re-
ductions in AF burden and AF- related complications 
(eg, stroke and heart failure), hospitalizations, costs, 
and mortality?
Integrated Care in Its Context of Health Systems
The published RCTs of integrated care have largely 
been from the Netherlands, Canada, and Australia. 
Will the benefits of integrated care generalize to other 
countries and healthcare settings? It is unclear how 
varied health systems, cultural differences, and pa-
tient populations diverse in age, sex, race/ethnicity, 
health literacy, and socioeconomic status will influ-
ence implementation and outcomes observed with 
integrated care.
Research Opportunities
1. Pursue explanatory RCTs and pragmatic studies 
broadening the range of outcomes for integrated AF 
care compared with usual care, including patient- 
reported outcomes (eg, quality of life), AF recurrence 
and burden (eg, assessed with remote monitoring), 
team- based outcomes (eg, efficiency and workforce), 
and intermediate outcomes (eg, physical functional 
status), as well as clinical end points (eg, stroke, 
heart failure, hospitalization, or death) and health-
care costs, understanding that interpreting results 
may be challenging with ongoing temporal trends in 
management changes (eg, improved oral anticoag-
ulation treatment). Critical to advancing the field will 
be to test integrated care approaches in a variety 
of healthcare settings and countries, including the 
United States and diverse patient populations.
2. Conduct outcomes research to compare integrated 
care strategies with guideline- based usual care and 
determine the benefits and risks of the individual 
elements fundamental to the integrated AF care 
approach (ie, active patient involvement, multidisci-
plinary team approach, use of mobile health technol-
ogy to support integrated care, and comprehensive 
treatment approach).
3. Conduct RCTs to investigate the efficacy for AF 
recurrence, progression, and complications of 
multidisciplinary, team- based integrated care in 
secondary prevention versus usual care, oversam-
pling specific subgroups of patients diverse in age, 
sex, race/ethnicity, and low socioeconomic sta-
tus, ensuring that interventions are appropriately 
tailored to diverse demographics. Identify sub-
groups of patients with AF (eg, AF type or comor-
bidities) most likely to benefit compared with usual 





Pharmacologic antiarrhythmic drug therapy con-
tinues to have limited efficacy in AF rhythm control 
and has adverse effects. Numerous risk factors 
for AF are associated with systemic inflamma-
tion, and anti- inflammatory agents have demon-
strated some efficacy at suppressing AF, albeit 
with significant adverse effects.84,85 The NLRP3 
(nucleotide- binding domain- like receptor protein 
3) inflammasome is a critical mediator for activa-
tion of the innate immune system, particularly in 
response to noninfectious molecules (Figure  6). 
This complex system is upregulated in human AF, 
and NLRP3 inhibition can prevent AF in animal 
models.86
The most powerful risk factor for AF is aging, which 
increases oxidative and metabolic stress, with a de-
cline in proteostasis integrity and mitochondrial func-
tion.87,88 Novel mediators of these processes have 
been identified as potential targets for prevention of 
AF, with encouraging preclinical preliminary results. 
Isolevuglandins are highly reactive products of lipid 
oxidation identified as key drivers of oxidative stress- 
related injury,89 and small- molecule isolevuglandin 
scavengers reduce AF in people with hypertension.90 
Dysfunctional proteostasis results in misfolded and 
aggregated proteins, and these cytotoxic oligomers 
can be prevented by isolevuglandin scavengers, 
such as 2- hydroxybenzylamine (NCT NCT04433091). 
Proteostasis also can be improved by the heat 
shock protein modulator geranylgeranylacetone, and 
both therapeutic strategies suppress AF in animal 
models.90,91
Mitochondrial metabolism is an important source 
of oxidative stress and a critical determinant of atrial 
energetics. AMP- activated protein kinase (AMPK) 
plays a central role in cellular metabolism and energy 
homeostasis, and reduced AMPK activity causes 
spontaneous AF in animal models.92 Drugs, such as 
metformin, that activate AMPK and promote mitoph-
agy have been associated with lower incidence of AF 
in certain observational and in vitro studies,93 making 
AMPK activity and mitochondrial function potentially 
attractive therapeutic targets. An RCT is currently test-
ing the effect of metformin on AF burden in a sam-
ple of patients both with and without diabetes mellitus 
(NCT03603912). Similarly, in a post hoc analysis of RCT 
data, treatment with sodium- glucose cotransporter- 2 
(SGLT2) inhibitors appeared to reduce new- onset and 
recurrent AF events in patients with type 2 diabetes 
mellitus.94 Like metformin, SGLT2 inhibitors also alle-
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dysfunction in a rat model of diabetes mellitus.95 It will 
be of interest to determine the effects of both met-
formin and SGLT2 inhibitors on AF burden in patients 
without diabetes mellitus.
Calcium overload promotes uncoupling of the elec-
tron transport chain, increasing mitochondrial genera-
tion of reactive oxygen species, reducing the efficiency 
of oxidative phosphorylation, and increasing oxidation 
of critical calcium cycling proteins that include calcium/
calmodulin- dependent protein kinase II and the ryan-
odine receptor.96 Mitochondrial targeted antioxidants 
and/or other agents that attenuate calcium leak from 
oxidized or hyperphosphorylated ryanodine receptors 
are likely to reduce ectopic atrial activity.97,98 Ryanodine 
receptor inhibitors reduce AF in animal models.99
Knowledge Gaps
Encouraging preliminary data on these novel media-
tors have generated additional questions and con-
troversies. Inflammasomes are primarily expressed 
in inflammatory cells, whereas the NLRP3 inflamma-
some also has been identified in atrial cardiomyo-
cytes. The relative contribution of NLRP3 activation 
in different cell populations to AF susceptibility as 
well as the optimal pharmacologic approach for in-
hibition remain unclear. The NLRP3 inflammasome 
is activated preferentially by damage rather than 
pathogen- associated molecules. The relative risk of 
infection with NLRP3 inhibitors compared with other 
anti- inflammatory agents, such as anti- cytokine 
targeted antibodies, like canakinumab, is un-
known. The best studied isolevuglandin scavenger, 
2- hydroxybenzylamine, has an elimination half- life in 
humans of 2 hours. New scavengers that preferen-
tially target the mitochondria and/or have longer half- 
lives have been developed, but it is unclear whether 
these properties translate to increased efficacy in 
preventing AF recurrence.
Dysfunctional proteostasis is improved by both 
isolevuglandin scavengers and geranylgeranylacetone 
Figure 6. Emerging pharmacologic targets for the prevention of atrial fibrillation (AF).
Molecular components involved in priming and activation of the NLRP3 (nucleotide- binding domain- like receptor protein 3) 
inflammasome, which has been linked to AF susceptibility. Obesity and ischemia promote endoplasmic reticulum (ER) stress and 
mitochondrial stress/dysfunction. These increase production of reactive oxygen species (ROS) and isolevuglandins (IsoLGs). ROS 
and IsoLGs promote aggregation of intracellular peptides/oligomers that can further impair mitochondrial function and activate 
NLRP3- induced cytokine production. AMP- activated protein kinase (AMPK) plays a central role in cellular metabolism and energy 
homeostasis, and reduced AMPK activity causes spontaneous AF in animal models. Increased spontaneous Ca2+ release from the 
sarcoplasmic reticulum contributes to atrial ectopy that can initiate episodes of AF. AP indicates action potential; ASC, apoptosis- 
associated speck- like protein containing a caspase recruitment domain; 2- HOBA, 2- hydroxybenzylamine; IL, interleukin; IP3, inositol 
trisphosphate; NF- κB, nuclear factor κ light chain enhancer of activated B cells; RCT, randomized controlled trial; RyR2 Ca2+, cardiac 
ryanodine receptor; TLR, toll- like receptor; TNFR, tumor necrosis factor receptor.
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(an inducer of heat shock gene expression), but which 
approach is most important and whether these ap-
proaches are redundant or additive have not been 
determined. Another unresolved issue is whether 
mitochondrial- targeted drugs will be effective in reduc-
ing excessive mitochondrial reactive oxygen species 
generation and whether it would influence AF recur-
rence or burden. It is unknown whether therapeutic 
agents that increase AMPK or anti– diabetes melli-
tus substances with additional cardiac effects, such 
as SGLT2 inhibitors, will be effective in patients with 
AF both with and without diabetes mellitus. Current 
agents that effectively suppress excessive calcium 
leak through ryanodine receptors can depress left ven-
tricular systolic function and/or blood pressure, and it 
remains uncertain whether compounds can be identi-
fied that lack these detrimental properties.
There is increasing awareness that pharmacother-
apies can have protective, neutral, and deleterious 
effects on cardiovascular outcomes. Unfortunately, 
although many trials of cardiovascular conditions and 
risk factors prespecify myocardial infarction and heart 
failure as outcomes, AF is often not specified a priori. 
Prespecifying AF onset, AF recurrence, AF progres-
sion, and AF- associated complications as outcomes 
for RCTs would accelerate the evidence base for the 
secondary prevention of AF.
Research Opportunities
1. Will targeting mitochondrial reactive oxygen spe-
cies production (eg, the isolevuglandin scavenger 
2- hydroxybenzylamine) prevent the development of 
AF in RCTs?
2. Will activating AMPK using metformin or other ap-
proaches enhance mitophagy and reduce arrhyth-
mia burden in human AF?
3. To reduce AF burden and progression, what is the 
optimal approach to preventing protein misfolding 
and the generation of cytotoxic protein oligomers?
4. RCTs of therapies for cardiovascular conditions (eg, 
heart failure and myocardial infarction) or risk factors 
should strongly consider prespecifying AF onset, 
recurrence, progression, and associated complica-
tions as secondary outcomes to accelerate the evi-
dence base for the secondary prevention of AF.
DISCUSSION
The NHLBI workshop participants identified multiple 
themes across our 6 domains of focus for the sec-
ondary prevention of AF recurrence, progression, and 
complications and identified critical research oppor-
tunities to advance the field (Table). There is a lack of 
mechanistic understanding on the pathophysiologi-
cal features (eg, fibrosis, inflammation, mitochondrial 
reactive oxygen species, and dysfunctional proteo-
stasis) linking risk factors and atrial electrical and 
structural remodeling to AF progression, remission, 
and complications. Furthermore, many risk factors 
for AF (eg, alcohol consumption, smoking, poor di-
etary patterns, obesity, diabetes mellitus, hyperten-
sion, sedentary lifestyle, and sleep disorders) are 
interrelated. It is unclear whether modification of a 
specific risk factor (eg, obesity) per se is sufficient, 
or must be addressed in the context of multiple risk 
factors to significantly prevent AF progression and 
complications.
Although strong observational data link risk fac-
tors to AF progression and complications, apart from 
anticoagulation for ischemic stroke prevention, RCTs 
for AF secondary prevention, which are vital to guide-
line development, have notable limitations. Previously 
conducted studies tend to be small to modest in 
size, are predominantly conducted in individuals of 
European ancestry, generally have been performed in 
the Netherlands, Australia, and Canada, typically are 
of short to medium duration, and examine intermedi-
ate end points (eg, AF burden), thus raising concerns 
about the studies’ generalizability and robustness of 
their interventions to alter important clinical outcomes 
(eg, dementia, heart failure, myocardial infarction, 
chronic kidney disease, and death). There is a need 
to prespecify AF- related end points (onset, recurrence, 
progression, and clinical complications) in RCTs of 
other conditions (eg, heart failure, myocardial infarc-
tion, hypertension, and diabetes mellitus).
There is a paucity of AF secondary prevention 
data in diverse populations (eg, older adults, women, 
individuals of Black, Hispanic, Indigenous, Pacific 
Islander, and Asian ancestry, and those with lower 
educational attainment and lower income) and im-
portant clinical subgroups (eg, individuals with 
HFpEF). Hence, it is not definitive that AF risk factor 
management (eg, weight loss, alcohol abstinence, 
smoking cessation, CR, improved sleep, and inte-
grated care) (1) has been designed to improve out-
comes in diverse patients with AF; (2) would have 
similar benefits in patients with different types of AF 
or varying comorbidities (eg, HFpEF); and (3) whether 
changes in AF burden will translate into improved 
clinical outcomes.
Fundamentally, wider implementation of AF sec-
ondary prevention requires pragmatic, randomized 
implementation trials to develop strategies that are 
scalable, sustainable, practical, resource efficient, and 
clinically effective in diverse patient populations. One 
avenue for scalability is digital health. The role of mo-
bile and wearable technology for the monitoring of AF 
burden and AF risk factors has been understudied for 
AF secondary prevention. It will be critical to investigate 
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Table. Prioritized Research Opportunities for the Secondary Prevention of AF
Weight loss and body composition
Identify populations in whom successful weight loss leads to reversal of the atrial substrate for AF, and determine the mechanisms associated with the 
reversibility of epicardial fat and atrial fibrosis/substrate, including weight loss per se and regression of the comorbidities associated with obesity
Develop and test effective, reproducible, scalable tools and strategies required to achieve and sustain significant weight loss and risk factor 
management over the long- term in diverse populations (eg, age, sex, race/ethnicity, and socioeconomic status) with AF and then implement the 
appropriate public health initiatives in different health systems and diverse populations
Conduct multicenter pragmatic RCTs of the effect of weight loss, including bariatric surgery, and risk factor management in diverse individuals with AF 
on AF recurrence, burden, progression, and outcomes, including stroke, cognitive decline, heart failure, myocardial infarction, quality of life, healthcare 
use, costs, and mortality
Alcohol, smoking, and diet
RCTs of specific interventions, including (1) alcohol reduction or abstinence; (2) intensive smoking cessation; (3) heart healthy diets (eg, DASH type, 
plant based, and Mediterranean) vs usual care should be conducted, evaluating their efficacy in reducing AF burden or recurrence, improving quality of 
life, and reducing complications among diverse patients (eg, age, sex, gender, race/ethnicity, and socioeconomic status) with AF, including those with 
new- onset disease, those with paroxysmal AF, postcardioversion, and individuals managed with pharmacological therapies or AF ablation procedures
Develop and test implementation strategies to scale and sustain lifestyle interventions proven to be effective for secondary prevention of AF, potentially 
including (1) reducing or avoiding alcohol; (2) intensive smoking cessation; (3) heart healthy diets in diverse communities and community- based 
settings; and study their effect on AF recurrence, AF burden, quality of life, healthcare use, and complications (eg, stroke, cognitive decline, heart 
failure, myocardial infarction, frailty, and death)
Test the effectiveness of digital health and wearable technologies to enhance adherence to effective lifestyle interventions (alcohol and smoking 
cessation and dietary modification) in diverse communities and community- based settings, and study their effect on AF burden, AF recurrence, quality 
of life, healthcare use, and AF complications
Cardiac rehabilitation
Observational studies and RCTs of CR should oversample understudied subgroups of patients with AF, including older adults, women, Black/Hispanic/
Asian/Pacific Islander/Indigenous individuals, HFpEF, and individuals with lower educational attainment/income. Outcomes should include success of 
risk factor modification (eg, if indicated smoking/alcohol cessation, weight loss, and control of blood pressure and diabetes mellitus) and AF- related 
symptoms, recurrence, progression, and clinical complications
RCTs should examine innovative implementation of CR strategies and their potential efficacy for reduced AF recurrence and complications in diverse 
representative AF populations:
• Harnessing technology: virtual care with apps and wearables.
• Home- based and hybrid models.
• High- intensity interval training vs lower- intensity regimens (eg, yoga and tai chi).
Substudies of CR observational studies and RCTs should examine the association of CR with AF- related biomarkers, including biomarkers of 
inflammation, genetic variation, - omics, aging, metabolome, and atrial imaging
Sleep disorders
Pursue explanatory RCTs and pragmatic studies broadening the range of outcomes for integrated AF care, including patient- reported outcomes (eg, 
quality of life), AF recurrence and burden (eg, assessed with remote monitoring), team- based outcomes (eg, efficiency and workforce), intermediate 
outcomes (eg, physical functional status), as well as clinical end points (eg, stroke, heart failure, hospitalization, or death) and healthcare costs with the 
comparator being usual care, understanding that interpreting results may be challenging with ongoing temporal trends in management changes (eg, 
improved oral anticoagulation treatment). Critical to advancing the field will be to test integrated care approaches in a variety of healthcare settings and 
countries, including the United States, and diverse patient populations
Conduct outcomes research to compare integrated care strategies with guideline- based usual care and determine the benefits and risks of the 
individual elements fundamental to the integrated AF care approach (ie, active patient involvement, multidisciplinary team approach, use of mobile 
health technology to support integrated care, and comprehensive treatment approach)
Conduct RCTs to investigate the efficacy for AF recurrence, progression, and complications of multidisciplinary, team- based integrated care in 
secondary prevention vs usual care, oversampling specific subgroups of patients diverse in age, sex, race/ethnicity, and low socioeconomic status, 
ensuring that interventions are appropriately tailored to diverse demographics. Identify subgroups of patients with AF (eg, AF type or comorbidities) 
most likely to benefit compared with usual care approach provided by one single healthcare professional
Integrated, team- based care
Pursue explanatory RCTs and pragmatic studies broadening the range of outcomes for integrated AF care compared with usual care, including patient- 
reported outcomes (eg, quality of life), AF recurrence and burden (eg, assessed with remote monitoring), team- based outcomes (eg, efficiency and 
workforce), and intermediate outcomes (eg, physical functional status), as well as clinical end points (eg, stroke, heart failure, hospitalization, or death) 
and healthcare costs, with the comparator being usual care, understanding that interpreting results may be challenging with ongoing temporal trends 
in management changes (eg, improved oral anticoagulation treatment). Critical to advancing the field will be to test integrated care approaches in a 
variety of healthcare settings and countries, including the United States, and diverse patient populations
Conduct outcomes research to compare integrated care strategies with guideline- based usual care and determine the benefits and risks of the 
individual elements fundamental to the integrated AF care approach (ie, active patient involvement, multidisciplinary team approach, use of mobile 
health technology to support integrated care, and comprehensive treatment approach)
Conduct RCTs to investigate the efficacy for AF recurrence, progression, and complications of multidisciplinary, team- based integrated care in 
secondary prevention vs usual care, oversampling specific subgroups of patients diverse in age, sex, race/ethnicity, and low socioeconomic status, 
ensuring that interventions are appropriately tailored to diverse demographics. Identify subgroups of patients with AF (eg, AF type or comorbidities) 
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of weight, alcohol/smoking/dietary habits, activity, CR, 
and sleep enhance the adherence, efficiency, and ef-
fectiveness of risk factor monitoring and modification 
for AF secondary prevention.
The secondary prevention of AF progression and 
its complications is of vital public health importance 
because ≈5.2 million individuals in the United States 
are known to have AF (2010 estimate).1 Since 1990, 
the global prevalence of AF has approximately dou-
bled to 59.7 million individuals in 2019.100 Furthermore, 
over the same time period, the age- standardized 
prevalence, disability- adjusted life years, and mortal-
ity have not substantially changed.100 Hence, AF will 
continue to lead to substantial morbidity as well as ex-
cess health care use, costs, and mortality. Although 
there are robust guidelines for the prevention of stroke 
after AF onset, there is a lack of class I evidence to 
strongly support the secondary prevention of demen-
tia, heart failure, myocardial infarction, chronic kidney 
disease, diminished quality of life, functional limitations, 
and increased healthcare use after AF is diagnosed. 
The authors hope this workshop will catalyze research 
that will advance the evidence base for the secondary 
prevention of the recurrence, progression, and compli-
cations of AF.
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Table S1. Published Cardiac Rehabilitation Studies. 
Study Study AF type CR versus control N(%) women N(%); Race Inc.; educ Mean age Results 
Studies included in Smart et al. meta-analysis48 
Hegbom F,  
J Cardiopulm 
Rehabil 2006101  
Characteristics 











Permanent AF  15/15 randomized  
13/15 analyzed 
Training: 13/0 ♂/♀ 
Control 13/2 ♂/♀ 
 






in health related QoL 
 
4/8 SF-35 scales improved 









26/25 randomized and 
analyzed aerobic 
interval training 12 
weeks vs. control 





NR 56±8* Aerobic interval training 
improved time in AF, AF 
symptom frequency & 
severity, QO2 peak, LVEF, 
QoL 
Osbak104  








Permanent AF 49 
25/24 randomized 
24/23 analyzed 12 wk 
aerobic exercise training 
vs. control 
♂:♀ ratio 0.75 Copenhagen, 
Denmark 
Race not specified 




capacity, 6 minute walk 
test, QoL assessed by MN 




(qi gong) training 
Prev Cardiol 2007 
Hospital of 
Lanciano, Italy 
16 week RCT qi 
Gong  
Vs. wait list 
control; single 
center 
Permanent AF 22/21 randomized and 
analyzed 16-week 
medically assisted qi 
gong training program 
30 men and 13 women  Italy 
Race NR 
<€18,000/yr 
Low Income 5 






qi gong training program 
associated with 114 
meters more walking at 
end of treatment & 57 
meters more at 16 
additional weeks 
Wahlstrom106 yoga 
Eur J Cardiovasc 
Nurs 2017 
Stockholm, Sweden  
RCT 
Yoga vs. control 
80 PAF 






Standard Rx vs. standard 
Rx + yoga 





NR 64±7 years Yoga with light 
movements & deep 
breathing led to improved 








Study Study AF type CR versus control N(%) women N(%); Race Inc.; educ Mean age Results 






at 30% of 
maximal 
inspiratory 





Permanent AF 19/19 randomized 
17/16 analyzed; 
inspiratory muscle 
training 30% max 
inspiratory pressure for 
15 min 2/day, 
7days/week 12weeks 
½ women Istanbul, Turkey 
Race NR 




strength & functional 
capacity 
Risom108 











28% persistent AF 















59 years improved physical 
capacity vs. usual care, 
but not mental health;  
-12 mo Mean VO2peak 
higher CR;  
-24 mo CR lower anxiety.  
- NS: admissions or death  
Skielboe111 

















RCT low (50%) or high 





76 pts,  
63 completed f/u; 
Low: 42% women 





N=2 “other” race 
NR Low: 64 
High: 61 
ITT analysis no statistical 
difference in burden of AF 
between low vs high 
intensity exercise 
Incidence rate ratio 0.74 
[95% CI, 0.29-1.91]; 
P=0.54 













HF with LVEF 
35%  
382 (17%) AF 
1602 (70%) SR 
308 (13%) other 
RCT exercise training vs. 
usual care 
 Median f/u 2.6 yrs 
30% women overall 
AF: 16% women 
















SR: 57 yr 
NS AF event rates by RCT 
in overall population or 
baseline AF; no 
interaction AF & exercise 
training functional status 








Study Study AF type CR versus control N(%) women N(%); Race Inc.; educ Mean age Results 
         
Studies not included in Smart et al. meta-analysis;48 published 2018 & later 
Reed113 





study pts with 
heart disease. 




permanent AF;  
Patients free of AF 
referents 
3 months CR 
AF n=47 vs. no AF n=47 
 
94 patients 




85% White NR 69.9 AF 
69.7 no AF 
Matched 
Observational; In patients 
with heart disease CR 
improved QoL to greater 
extent in pts w/o AF vs. 
with AF 
Alharbi114 Can J 
Cardiol. 2019; 
 




566 newly dx AF 
133 (23.5%) 
underwent CR; 
197 ()34.8% AFC; 
236 (41.7%) usual 
specialist care 
AF ED visits & CV 
hospitalizations 7.5% 




CR: 35%  
AFC: 45% 
UC: 45% 
NR, Canada NR Age ≥75 yrs  
CR: 22%  
AFC: 24% 
UC: 27.5% 
Propensity match vs. CR: 
UC OR 4.91 [95% CI, 2.09-
11.53]; AFC OR, 2.75 [95% 
CI, 1.14-6.6] 












30 CR 6-month exercise-
based CR; 2 dropped out 
analyzed 28 
vs. 31 control 
19 women 20% 
48 men 80% 
NR 
Japanese 
NR 66±9 years CR, significant increase 6-
min walk test, handgrip & 
leg strength, LVEF, sign. 
Decrease CRP; NS in AF 
recurrence 
Rienstra52 Eur Heart 











control vs usual care 
119/126 
193 men (79%) 
52 women (21%) 
NR NR 65±9 years Improvement in sinus 
rhythm maintenance, BP, 
NT-proBNP  






and persistent AF 
(52%) 
12 week CR; 28/30; 6 
dropped out 24 vs 28 
18 women (35%) 
34 men (65%) 
NR NR 61 years Improved QOL at 6 


















Permanent AF PT-X Physiotherapist-led 
exercise CR with 
physical activity (60 min 
group session & home-
based exercise 2/wk) vs. 
PAP physical activity 
prescription (40 min 
walking 4x/wk) 
96 pts; 28 women NR 
Swedish 




PAP significant increase 
energy expenditure 
NS: Health-related QOL 




PI: R Parkash 
Multi-center 






Home-based CR, alcohol 
reduction, sleep apnea, 










AF, atrial fibrillation; AFC, specialized atrial fibrillation clinic; BP, blood pressure; CR, cardiac rehabilitation; educ, education; HF, heart failure; inc, income; LVEF, left 










Table S2. Cardiac Rehabilitation (CR) Studies in Clinicaltrial.gov. 
NCT Number  Title  Status Conditions Interventions Characteristics Sponsor/Collaborators Dates Locations Design 
NCT04414007 
PI: Guozhen Sun, MD 
& Zhipeng BAO 




























June 30, 2022 
•The First Affiliated hospital of 
Nanjing 







at 12 months 
NCT04092166 
PI: Suneet Mittal, MD 


























•The Valley Hospital, Paramus, 
New 










































































of recurrences of 









NCT Number  Title  Status Conditions Interventions Characteristics Sponsor/Collaborators Dates Locations Design 
NCT04500184 






























June 1, 2017 
Study 
Completion: 
May 31, 2020 
 
•Samsung Medical Center, Seoul, 










PI: Albert Marni 

































See Table S1 
Rienstra52 
 
PIs: Marco Alings, 
MD, PhD; Isabelle C 
Van Gelder, MD, 







for Prevention of 
Early 
Atrial Fibrillation 












•I.C. Van Gelder 
•The Interuniversity 












•Biotronik SE & Co.KG 
•Abbott Medical 
Devices 









•Onze Lieve Vrouwe Gasthuis, 
Amsterdam 
•Hospital Rijnstate, Arnhem/Velp, 
•Ter Gooi Hospital, Blaricum, 
•Amhia Hospital, Breda 
•Ommelander Hospital Group, 
Delfzijl, 
•Deventer Hospital, Deventer, 
•Oosterscheldeziekenhuis, Goes, 
•Martini Hospital, Groningen, 
•University Medical Center 
Groningen, Groningen 
•and 10 more 
Long term follow 
up of RACE 3 
which is already 
published and 









NCT Number  Title  Status Conditions Interventions Characteristics Sponsor/Collaborators Dates Locations Design 
NCT02493387 
See Borland Table S1; 
Study Director: Asa 













































to CR clinic 













Urban safety-net hospital 









PIs: Andrea Natale, 


























•Texas Cardiac Arrhythmia 
Institute, 












PI: Jennifer L Reed, 
PhD 
Exercise Training 







































NCT Number  Title  Status Conditions Interventions Characteristics Sponsor/Collaborators Dates Locations Design 
NCT03910192 

























































































































NCT Number  Title  Status Conditions Interventions Characteristics Sponsor/Collaborators Dates Locations Design 
NCT03724383 










































British Columbia, Canada 
•Richmond Hospital Cardiac 
Rehabilitation, Richmond 
•Richmond Health Services, 
Richmond 
•Garratt Wellness Centre, 
Richmond, 
•Richmond Cardiology Clinic, 
Richmond 
•Gordon and Leslie Diamond 
Health Care Centre, Vancouver 
•Live Well Clinic, Vancouver 







frequent of AF 










of Patients After 












Center for Preventive 
Medicine 
•National Medical 
Research Center for 














See Table S1 
Risom109 PIs: Signe S 
Risom, RN, MSc; 
Selina K Berg, MScN, 
PhD.; Ann-Dorthe O 
Zwisler, MD, PhD; 












































NCT Number  Title  Status Conditions Interventions Characteristics Sponsor/Collaborators Dates Locations Design 
NCT03068169 
Balsam Cardiol J 2018 
Design paper121 PIs: 
Renata Główczyńska, 
PhD; Paweł Balsam, 












after PVI for 
AF 










Warsaw, Mazowieckie, Poland 
•Department of Pediatric 
Cardiology 
and General Pediatrics, Medical 
University of Warsaw  
•Department of Clinical Nursing, 






using an ECG 
shirt 
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